Interview with Ulf Schneider, Managing Partner, RUSSIA CONSULTING
You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind…
Address: 112 LIGOVSKY PROSPECT, SAINT-PETERSBURG, 191119,Russia
Tel: +7 (812) 710-82-25
Web: http://www.polysan-ru.com/
Scientific Technological Pharmaceutical Firm ‘POLYSAN’ Ltd. was founded in December 1992. Since then ‘POLYSAN’ turned into Pharmaceutical Firm, which develops original preparations and is capable of meeting competition with both domestic and foreign companies. Nowadays the Firm ranks among the leaders of pharmaceutical industry in Russia and takes constant care of application of science and state-of-the-art technology achievements to production aiming further improvement of output quality.
The main goal of “POLYSAN” is development of original high-efficient medicinal preparations with reasonable price for patients.
The uniqueness of the company consists of organization the whole preparation cycle from idea to development and registration, production and sale. In order to fulfill the above task the Firm has modern Scientific laboratory, Pharmaceutical production complex in Saint Petersburg and Substances production complex “POLISINTEZ” Ltd. in Belgorod (South of Russia).
The preparations designed and produced by the Firm have been successfully sold on both domestic and foreign markets.
Scientific Technological Pharmaceutical Firm ‘POLYSAN’ has two directions of its activity.
Firstly – “POLYSAN” is specialized on development of preparations for treating “socially important” diseases that lead to the long disability, invalidity: mass viral infections (hepatitis B, C, flue infections, HIV), bacterial infections and heavy diseases such as acute cerebrovascular disorder (brain infarction), ischemia and others.
Secondly – “POLYSAN” is producer of metabolic preparations on succinic acid basis possessed anti-oxidantive activity.
You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind…
The following is an interview with Dr. Smirnov, as well as Dr. Dmitri Pavlovich, Director, Clinical Operations Russia Quintiles very recently announced the launch of its first commercial project in…
The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and Operations, CEE, CIS and Russia Quintiles very recently announced the launch of…
GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s…
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
Pepeliaev, Goltsblat & Partners and the major UK firm Berwin Leighton Paisner (BLP). It calls itself the first international Russian law firm. Can you explain to our readers the rationale…
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
You were working for GSK since 2003 before joining Galderma this year. Some within the industry might view Galderma as a step down from the third-ranked pharmaceutical company in the…
Janssen recently signed memorandums of understanding with both the Skolkovo Foundation and ChemRar. Can you describe the strategic parameters and intended outcomes of these agreements? How do they factor into…
Mr. Demidov, you are one of the pioneers of market research studies in Russia. There is a quote you like to use: ‘Market research is a business in the United…
How would you describe CMS’s own presence in the life sciences field in Russia, and what unique competitive advantages does the firm bring to this area of practice? Over the…
With the announcement of the Pharma 2020 strategy to develop the domestic pharmaceutical industry, multinational companies have pledged an excess of $1Bn in investment into local infrastructure. Servier, however, preempted…
See our Cookie Privacy Policy Here